2026-05-17T05:52:39Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/193722024-11-29T08:21:28Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Monge Corella, Susana author Humphreys, James author Nicolay, Nathalie author Braeye, Toon author Van Evercooren, Izaak author Holm Hansen, Christian author Emborg, Hanne-Dorthe author Sacco, Chiara author Mateo-Urdiales, Alberto author Castilla, Jesús author Martínez-Baz, Iván author de Gier, Brechje author Hahné, Susan author Meijerink, Hinta author Kristoffersen, Anja Bråthen author Machado, Ausenda author Soares, Patricia author Nardone, Anthony author Bacci, Sabrina author Kissling, Esther author Nunes, Baltazar author VEBIS-EHR Working Group author 2024-04 Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA. Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. 10.1111/irv.13292 1750-2659 Influenza and other respiratory viruses 38654485 http://hdl.handle.net/20.500.12105/19372 Cohort design COVID-19 Electronic health records Hospitalisation Multicountry study SARS-CoV-2 Vaccine effectiveness Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study